MGTX241220C10000
- 0.20
- 0.000.00%
MeiraGTx Holdings Newsroom
MeiraGTx Holdings Is Maintained at Outperform by RBC Capital
MeiraGTx Hldgs Analyst Ratings
RBC Capital Maintains MeiraGTx Holdings(MGTX.US) With Buy Rating, Raises Target Price to $11
BofA Securities Maintains MeiraGTx Holdings(MGTX.US) With Buy Rating, Cuts Target Price to $12
MeiraGTx Hldgs Analyst Ratings
RBC Capital Maintains MeiraGTx Holdings(MGTX.US) With Buy Rating, Cuts Target Price to $9
RBC Adjusts Price Target on MeiraGTx Holdings to $9 From $11, Maintains Outperform Rating, Speculative Risk
Analysts Offer Insights on Healthcare Companies: Meiragtx Holdings (MGTX), Spruce Biosciences (SPRB) and Gossamer Bio (GOSS)
MeiraGTx Holdings Price Target Announced at $36.00/Share by Chardan Capital
MeiraGTx Hldgs Analyst Ratings
Meiragtx Holdings (MGTX) Receives a Buy From RBC Capital
MeiraGTx Hldgs Analyst Ratings
Buy Rating Affirmed: Meiragtx Holdings' Promising Pipeline and Strategic Partnerships Set Stage for Growth
RBC Capital Sticks to Their Buy Rating for Meiragtx Holdings (MGTX)
Analysts Offer Insights on Healthcare Companies: Vericel (VCEL), Irhythm Technologies (IRTC) and Meiragtx Holdings (MGTX)
Analysts' Opinions Are Mixed on These Healthcare Stocks: NeuroPace (NPCE), Meiragtx Holdings (MGTX) and Jazz Pharmaceuticals (JAZZ)
RBC Capital Sticks to Its Buy Rating for Meiragtx Holdings (MGTX)
Buy Rating on Meiragtx Holdings: Promising Future With Sanofi Deal and Revolutionary Riboswitch Technology
RBC Capital Maintains Outperform on MeiraGTx Hldgs, Lowers Price Target to $11
MeiraGTx Hldgs Analyst Ratings